Abstract: The present disclosure provides anti-PD-1 antibodies with a single heavy chain variable domain that specifically binds to human PD-1 protein and which are capable of binding to immune cells, with or without increasing, decreasing, inhibiting, and/or blocking immune regulatory effects mediated by PD-1, including the immune response mediated by activated T cells. The present disclosure also provides methods of using the anti-PD-1 antibodies (and compositions thereof) to treat diseases and conditions mediated by activated T cells in the immune response, including cancer, autoimmune disorders, and viral infections.

Abstract: The present disclosure provides anti-CD8 antibodies with a single heavy chain variable domain that specifically binds to human CD8 protein and which are capable of binding to CD8+ immune cells, with or without increasing, decreasing, inhibiting, and/or blocking immune regulatory effects mediated by CD8, including the immune response mediated by activated CD8+ T cells. The present disclosure also provides methods of using the anti-CD8 antibodies (and compositions thereof) to treat diseases and conditions mediated by activated CD8+ T cells in the immune response, including cancer, autoimmune disorders, and viral infections.